Early on, IL-1 blockade esp using anakinra, got a lot of attention Canakinumab (CAN-COVID) trial: negative https://t.co/lZnGQEmsJp #ACR21 https://t.co/0QjyWIusH0
So far, Altmetric has seen
118 X posts from 109 X users, with an upper bound of 1,053,565 followers.
8,620 followers
43 followers
@DrAiLynTan @NatRevImmunol https://t.co/QPrCDfjUF4 But canakinumab did not improve survival. What are we still missing?
807 followers
RT @JAMA_current: Among patients hospitalized with severe #COVID19, treatment with canakinumab, compared with placebo, did not significantl…
954 followers
JAMA CAN-COVID Trial https://t.co/Id9rigvmle Patients hospitalized with severe COVID-19, canakinumab vs placebo, did not significantly increase the likelihood of survival without IMV by D29 (88.8% vs 85.7%, diff 3.1%, OR 1.39, 95% CI 0.76-2.54, p=0.29) htt